Clinical Trials Browser

Phase 1/2 × Recruiting × pertuzumab × Clear all

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT04588545 2026-02-09

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Phase 1/2 Recruiting

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT04750122 2021-04-01

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

Phase 1/2 Recruiting

HER2-positive Early Breast Cancer